Immune cells derived from induced pluripotent stem cells: a new cell source for cancer immunotherapy.
Clinical results have shown promising therapeutic potential of engineered T cell express- ing TCR (T cell antigen receptor) or CAR (chimeric antigen receptor). However, high cost, donor cell availability, complicated procedure of genetic engineering prevent their wider ap- plication. iPSCs (induced pluripotent stem cells) are attractive source of immune cells includ- ing T cells and dendritic cells, and may provide an unlimited cell source for adoptive immune cell therapy. Genetic engineering of iPSCs may confer enhanced anti-tumor activity and ena- ble the escape from immune rejection. Here, we discuss the potential of iPSCs as a novel source of anti-tumor immune cells.